New Releases from NCBI BookshelfIvosidenib (Tibsovo): Indication: Ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy: Reimbursement Recommendation [Internet].​Ivosidenib (Tibsovo): Indication: Ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy: Reimbursement Recommendation [Internet].